TITLE

F-radiolabeled analogs of exendin-4 for PET imaging of GLP-1 in insulinoma

AUTHOR(S)
Kiesewetter, Dale; Gao, Haokao; Ma, Ying; Niu, Gang; Quan, Qimeng; Guo, Ning; Chen, Xiaoyuan
PUB. DATE
March 2012
SOURCE
European Journal of Nuclear Medicine & Molecular Imaging;Mar2012, Vol. 39 Issue 3, p463
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose: Glucagon-like peptide type 1 (GLP-1) is an incretin peptide that augments glucose-stimulated insulin release following oral consumption of nutrients. Its message is transmitted via a G protein-coupled receptor called GLP-1R, which is colocalized with pancreatic β-cells. The GLP-1 system is responsible for enhancing insulin release, inhibiting glucagon production, inhibiting hepatic gluconeogenesis, inhibiting gastric mobility, and suppression of appetite. The abundance of GLP-1R in pancreatic β-cells in insulinoma, a cancer of the pancreas, and the activity of GLP-1 in the cardiovascular system have made GLP-1R a target for molecular imaging. Methods: We prepared F radioligands for GLP-1R by the reaction of [F]FBEM, a maleimide prosthetic group, with [Cys] and [Cys] analogs of exendin-4. The binding affinity, cellular uptake and internalization, in vitro stability, and uptake and specificity of uptake of the resulting compounds were determined in an INS-1 xenograft model in nude mice. Results: The [F]FBEM-[Cys]-exendin-4 analogs were obtained in good yield (34.3 ± 3.4%, n = 11), based on the starting compound [F]FBEM), and had a specific activity of 45.51 ± 16.28 GBq/μmol (1.23 ± 0.44 Ci/μmol, n = 7) at the end of synthesis. The C-terminal isomer, [F]FBEM-[Cys]-exendin-4, had higher affinity for INS-1 tumor cells (IC 1.11 ± 0.057 nM) and higher tumor uptake (25.25 ± 3.39 %ID/g at 1 h) than the N-terminal isomer, [F]FBEM-[Cys]-exendin-4 (IC 2.99 ± 0.06 nM, uptake 7.20 ± 1.26 %ID/g at 1 h). Uptake of both isomers into INS-1 tumor, pancreas, stomach, and lung could be blocked by preinjection of nonradiolabeled [Cys]-exendin-4 ( p < 0.05). Conclusion: [F]FBEM-[Cys]-exendin-4 and [F]FBEM-[Cys]-exendin-4 have high affinity for GLP-1R and display similar in vitro cell internalization. The higher uptake into INS-1 xenograft tumors exhibited by [F]FBEM-[Cys]-exendin-4 suggests that this compound would be the better tracer for imaging GLP-1R.
ACCESSION #
71509378

 

Related Articles

  • Interaction of insulin, glucagon-like peptide-1, gastric inhibitory polypeptide, and appetite... Lavin, Jacquelynne H.; Wittert, Gary A. // American Journal of Clinical Nutrition;Sep98, Vol. 68 Issue 3, p591 

    Presents a number of studies which investigated the link between plasma insulin, gastric inhibitory polypeptide, glucagon-like peptide 1 and appetite rating in response to intraduodenal carbohydrate. Number of men who participated in the study; Energy content and macronutrient composition of...

  • GLP-1�Receptor Scanning for Imaging of Human Beta Cells Transplanted in Muscle. Pattou, Francois; Kerr-Conte, Julie; Wild, Damian // New England Journal of Medicine;9/23/2010, Vol. 363 Issue 13, p1289 

    A letter to the editor regarding a study wherein glucagon-like peptide 1 (GLP-1) receptor scanning was used for the successful imaging of autologous human beta cells in 48-year-old woman who had at least 80 percent of her pancreas resected for an insulinoma, is presented.

  • Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results. Gotthardt, Martin; Fischer, Marc; Naeher, Inga; Holz, Josefin B.; Jungclas, Hartmut; Fritsch, Hans-Walter; Béhé, Martin; Göke, Burkhard; Joseph, Klaus; Behr, Thomas M. // European Journal of Nuclear Medicine & Molecular Imaging;2002, Vol. 29 Issue 5, p597 

    The non-invasive detection of insulinomas remains a diagnostic problem that is not solved by means of somatostatin receptor scintigraphy. We investigated the biokinetics and specificity of uptake and degradation of the incretin hormone glucagon-like peptide-1 (GLP-1) in a rat insulinoma cell...

  • Glucagon-like peptide 1 receptor plays a critical role in geniposide-regulated insulin secretion in INS-1 cells. Guo, Li-xia; Xia, Zhi-ning; Gao, Xue; Yin, Fei; Liu, Jian-hui // Acta Pharmacologica Sinica;Feb2012, Vol. 33 Issue 2, p237 

    Aim:To explore the role of the glucagon-like peptide 1 receptor (GLP-1R) in geniposide regulated insulin secretion in rat INS-1 insulinoma cells.Methods:Rat INS-1 insulinoma cells were cultured. The content of insulin in the culture medium was measured with ELISA assay. GLP-1R gene in INS-1...

  • Treatment of Type 1 Diabetic Patients with Glucagon-Like Peptide-1 (GLP-1) and GLP-1R Agonists. Kielgast, Urd; Holst, Jens J.; Madsbad, Sten // Current Diabetes Reviews;2009, Vol. 5 Issue 4, p266 

    GLP-1 (glucagon-like peptide-1) is a peptide hormone secreted from endocrine cells in the intestinal mucosa in response to meals. The major effects of GLP-1 are to increase glucose-induced insulin secretion and reduce glucagon release, but GLP-1 also inhibits gastric emptying rate and reduces...

  • GLP-1 Agonists and Satiety. Bello, Nicholas T.; Moran, Timothy H. // Immunology, Endocrine & Metabolic Agents - Medicinal Chemistry;Dec2008, Vol. 8 Issue 4, p311 

    Glucagon-like peptide - 1 (GLP-1, 7-36 amide) is an intestinal hormone that is released in response to the luminal presences of nutrients. GLP-1 and related mimetic drugs are potent stimulators of pancreatic insulin, a response that is beneficial for the management of non-insulin dependent...

  • GLP-1 RECEPTOR AGONIST THERAPY. Hensler, Paula // GP: General Practitioner;1/21/2013 Diabetes Supplement, p2 

    The article focuses on glucagon-like peptide 1 (GLP-1) receptor agonist therapy and its role in treatment pathway for type 2 diabetes. The effects of GLP-1 receptor agonists include increase in insulin production after meals, satiety and reduced appetite and reduction in glucagon secretion. They...

  • Occurrence of Spontaneous Pancreatic Lesions in Normal and Diabetic Rats: A Potential Confounding Factor in the Nonclinical Assessment of GLP-1-Based Therapies. Chadwick, Kristina D.; Fletcher, Anthony M.; Parrula, M. Cecilia; Bonner-Weir, Susan; Mangipudy, Raja S.; Janovitz, Evan; Graziano, Michael J.; Roy, Denis; Reilly, Timothy P. // Diabetes;Apr2014, Vol. 63 Issue 4, p1303 

    Glucagon-like peptide 1-based therapies, collectively described as incretins, produce glycemic benefits in the treatment of type 2 diabetes. Recent publications raised concern for a potential increased risk of pancreatitis and pancreatic cancer with incretins based in part on findings from a...

  • GLP-1-Based Therapy for Diabetes: What You Do Hot Know Can Hurt You. Butler, Peter C.; Dry, Sarah; Elashoff, Robert // Diabetes Care;Feb2010, Vol. 33 Issue 2, p453 

    The authors focus on a study which suggests that glucagon-like peptide 1 (GLP-1) class of drugs has a good safety profile and is appropriate for an early treatment choice for type 2 diabetes. They discuss the risk profile of GLP-1 drugs. They note that there are concerns that GLP-1 class of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics